Khalis Mustafayev, Mert Ahmet Kuşkucu, Fatma Nihan Akkoç-Mustafayev, Seval Ürkmez, Bilgül Mete, Gökhan Aygün
{"title":"临床和分子方法对重症监护病房念珠菌病的早期诊断:一项前瞻性观察研究。","authors":"Khalis Mustafayev, Mert Ahmet Kuşkucu, Fatma Nihan Akkoç-Mustafayev, Seval Ürkmez, Bilgül Mete, Gökhan Aygün","doi":"10.36519/idcm.2024.443","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Early diagnosis and treatment of candidemia in intensive care units (ICUs) remain a significant challenge globally because of the lack of well-established non-culture-based diagnostic methods. This study aimed to evaluate risk factors in critically ill ICU patients, develop a unique <i>Candida</i> score, and create a real-time polymerase chain reaction (PCR) assay for the early diagnosis of candidemia.</p><p><strong>Materials and methods: </strong>The study was conducted in three phases: 1) Retrospective analysis of 100 ICU patients from İstanbul University-Cerrahpaşa between January 2017 and December 2018 to identify risk factors for invasive candidiasis, 2) development of Cerrahpaşa <i>Candida</i> score based on these findings, and 3) prospective evaluation of 75 ICU patients, applying the newly created Cerrahpaşa <i>Candida</i> score and implementing a rapid PCR-based test on whole blood samples. The PCR assay was part of a development study and was not used for scoring or clinical diagnostic evaluation. Specific primer pairs and EvaGreen® dye (Biotium Inc., USA) were used to differentiate between <i>Candida albicans</i> and <i>Candida parapsilosis</i> isolates through melting curve analysis of real-time PCR amplicons. The PCR test demonstrated a detection limit of 10 CFU/mL.</p><p><strong>Results: </strong>In the retrospective analysis, key risk factors for candidemia were identified, including sepsis, intra-abdominal infections, hospitalization within the last three months, prolonged antibiotic use (>1 week), <i>Candida</i> colonization, percutaneous endoscopic gastrostomy, central venous catheter, and acute kidney injury ( <i>p<</i>0.05). During the prospective phase, which evaluated 75 ICU patients, a Cerrahpaşa <i>Candida</i> score cutoff value of ≥4 points was established as significantly associated with an increased risk of candidemia (<i>p</i><0.05). The Cerrahpaşa <i>Candida</i> score and PCR assay, targeting the internal transcribed spacer (ITS) and D1/D2 regions, showed clinical utility for early diagnosis.</p><p><strong>Conclusion: </strong>The Cerrahpaşa <i>Candida</i> score and real-time PCR test developed in this study offer promising tools for guiding antifungal therapy in ICU patients, potentially reducing unnecessary antifungal use. However, improvements in PCR sensitivity are necessary. Further multicenter studies with larger patient cohorts are recommended to validate the clinical effectiveness of these diagnostic tools.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"6 4","pages":"306-319"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687236/pdf/","citationCount":"0","resultStr":"{\"title\":\"Early Diagnosis of Candidemia in the Intensive Care Unit by Clinical and Molecular Methods: A Prospective Observational Study.\",\"authors\":\"Khalis Mustafayev, Mert Ahmet Kuşkucu, Fatma Nihan Akkoç-Mustafayev, Seval Ürkmez, Bilgül Mete, Gökhan Aygün\",\"doi\":\"10.36519/idcm.2024.443\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Early diagnosis and treatment of candidemia in intensive care units (ICUs) remain a significant challenge globally because of the lack of well-established non-culture-based diagnostic methods. This study aimed to evaluate risk factors in critically ill ICU patients, develop a unique <i>Candida</i> score, and create a real-time polymerase chain reaction (PCR) assay for the early diagnosis of candidemia.</p><p><strong>Materials and methods: </strong>The study was conducted in three phases: 1) Retrospective analysis of 100 ICU patients from İstanbul University-Cerrahpaşa between January 2017 and December 2018 to identify risk factors for invasive candidiasis, 2) development of Cerrahpaşa <i>Candida</i> score based on these findings, and 3) prospective evaluation of 75 ICU patients, applying the newly created Cerrahpaşa <i>Candida</i> score and implementing a rapid PCR-based test on whole blood samples. The PCR assay was part of a development study and was not used for scoring or clinical diagnostic evaluation. Specific primer pairs and EvaGreen® dye (Biotium Inc., USA) were used to differentiate between <i>Candida albicans</i> and <i>Candida parapsilosis</i> isolates through melting curve analysis of real-time PCR amplicons. The PCR test demonstrated a detection limit of 10 CFU/mL.</p><p><strong>Results: </strong>In the retrospective analysis, key risk factors for candidemia were identified, including sepsis, intra-abdominal infections, hospitalization within the last three months, prolonged antibiotic use (>1 week), <i>Candida</i> colonization, percutaneous endoscopic gastrostomy, central venous catheter, and acute kidney injury ( <i>p<</i>0.05). During the prospective phase, which evaluated 75 ICU patients, a Cerrahpaşa <i>Candida</i> score cutoff value of ≥4 points was established as significantly associated with an increased risk of candidemia (<i>p</i><0.05). The Cerrahpaşa <i>Candida</i> score and PCR assay, targeting the internal transcribed spacer (ITS) and D1/D2 regions, showed clinical utility for early diagnosis.</p><p><strong>Conclusion: </strong>The Cerrahpaşa <i>Candida</i> score and real-time PCR test developed in this study offer promising tools for guiding antifungal therapy in ICU patients, potentially reducing unnecessary antifungal use. However, improvements in PCR sensitivity are necessary. Further multicenter studies with larger patient cohorts are recommended to validate the clinical effectiveness of these diagnostic tools.</p>\",\"PeriodicalId\":519881,\"journal\":{\"name\":\"Infectious diseases & clinical microbiology\",\"volume\":\"6 4\",\"pages\":\"306-319\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687236/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases & clinical microbiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36519/idcm.2024.443\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases & clinical microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/idcm.2024.443","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:在重症监护病房(icu)的早期诊断和治疗念珠菌病仍然是全球的一个重大挑战,因为缺乏完善的非培养基础的诊断方法。本研究旨在评估重症ICU患者的危险因素,建立独特的念珠菌评分,并建立实时聚合酶链反应(PCR)检测方法,用于念珠菌病的早期诊断。材料与方法:本研究分三个阶段进行:1)回顾性分析2017年1月至2018年12月İstanbul university - cerrahpa 100例ICU患者,以确定侵袭性念珠菌病的危险因素;2)基于这些结果制定cerrahpa念珠菌评分;3)对75例ICU患者进行前瞻性评估,应用新创建的cerrahpa念珠菌评分,并对全血样本进行快速pcr检测。PCR检测是一项发展研究的一部分,不用于评分或临床诊断评估。采用特异性引物对和EvaGreen®染料(Biotium Inc., USA)通过实时PCR扩增物的熔化曲线分析来区分白色念珠菌和假丝酵母菌。PCR检测限为10 CFU/mL。结果:通过回顾性分析,确定了念珠菌感染的关键危险因素,包括脓毒症、腹腔内感染、最近3个月内住院、抗生素使用时间延长(>1周)、念珠菌定植、经皮内镜胃造口术、中心静脉置管、急性肾损伤(p0.05)。在前瞻性阶段,对75例ICU患者进行评估,cerrahpa念珠菌评分临界值≥4分与念珠菌血症风险增加显著相关(pCandida评分和PCR检测,针对内部转录间隔区(ITS)和D1/D2区域,显示早期诊断的临床应用价值。结论:本研究建立的cerrahpa念珠菌评分和实时PCR检测方法为指导ICU患者的抗真菌治疗提供了有希望的工具,可能减少不必要的抗真菌药物使用。然而,提高PCR的敏感性是必要的。进一步的多中心研究推荐更大的患者队列来验证这些诊断工具的临床有效性。
Early Diagnosis of Candidemia in the Intensive Care Unit by Clinical and Molecular Methods: A Prospective Observational Study.
Objective: Early diagnosis and treatment of candidemia in intensive care units (ICUs) remain a significant challenge globally because of the lack of well-established non-culture-based diagnostic methods. This study aimed to evaluate risk factors in critically ill ICU patients, develop a unique Candida score, and create a real-time polymerase chain reaction (PCR) assay for the early diagnosis of candidemia.
Materials and methods: The study was conducted in three phases: 1) Retrospective analysis of 100 ICU patients from İstanbul University-Cerrahpaşa between January 2017 and December 2018 to identify risk factors for invasive candidiasis, 2) development of Cerrahpaşa Candida score based on these findings, and 3) prospective evaluation of 75 ICU patients, applying the newly created Cerrahpaşa Candida score and implementing a rapid PCR-based test on whole blood samples. The PCR assay was part of a development study and was not used for scoring or clinical diagnostic evaluation. Specific primer pairs and EvaGreen® dye (Biotium Inc., USA) were used to differentiate between Candida albicans and Candida parapsilosis isolates through melting curve analysis of real-time PCR amplicons. The PCR test demonstrated a detection limit of 10 CFU/mL.
Results: In the retrospective analysis, key risk factors for candidemia were identified, including sepsis, intra-abdominal infections, hospitalization within the last three months, prolonged antibiotic use (>1 week), Candida colonization, percutaneous endoscopic gastrostomy, central venous catheter, and acute kidney injury ( p<0.05). During the prospective phase, which evaluated 75 ICU patients, a Cerrahpaşa Candida score cutoff value of ≥4 points was established as significantly associated with an increased risk of candidemia (p<0.05). The Cerrahpaşa Candida score and PCR assay, targeting the internal transcribed spacer (ITS) and D1/D2 regions, showed clinical utility for early diagnosis.
Conclusion: The Cerrahpaşa Candida score and real-time PCR test developed in this study offer promising tools for guiding antifungal therapy in ICU patients, potentially reducing unnecessary antifungal use. However, improvements in PCR sensitivity are necessary. Further multicenter studies with larger patient cohorts are recommended to validate the clinical effectiveness of these diagnostic tools.